Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 51+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Day One Biopharmaceuticals, Inc.· Updated 18 Jun 2026

  “Development discontinued.”Registry text, quoted unchanged. Source

• Terminated

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Bolt Biotherapeutics, Inc.· Updated 15 Sept 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

  NCT05356897· Academic and Community Cancer Research United· Updated 19 Sept 2024

  “no sites were regulatory ready and the SC took the study to a different group.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

  NCT04704661· National Cancer Institute (NCI)· Source

• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Boehringer Ingelheim· Source

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· AstraZeneca· Source

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Source

• Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

  NCT06449989· Blokhin's Russian Cancer Research Center· Source

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  NCT06625775· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source

• A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

  NCT07691489· Memorial Sloan Kettering Cancer Center· Source

• Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

  NCT04899908· Brigham and Women's Hospital· Source

• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

  NCT06136897· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 337
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 210
• Deep Learning 142
• Cohort Studies 316
• Genome-Wide Association Study 65

• Vascular Proliferation Index Via a Single-Cell Analysis Is a Superior Prognostic Biomarker to Microvessel Density in Stage II/III Colorectal Cancer.

  Anticancer Res, Oct 2026

• A Multimodal Framework to Assess Patient-Derived Colon Tumor Organoid-Immune Cell Co-cultures.

  J Vis Exp, Sept 2026

• Spectral cytometry-based immune profiling coupled with machine learning identifies circulating Th1-like cells as a blood biomarker for advanced colorectal adenomas.

  Eur J Cancer, Aug 2026

• Comparison of Tissue Preparations to Identify and Phenotype T Cells in Human Colorectal Tumor Tissue.

  Cytometry A, Jun 2026

• Cytometry by Time-of-Flight for Profiling Therapeutic Response in Colorectal Cancer: Strengths, Limitations, and Translational Challenges.

  Anticancer Res, May 2026

• Perforin and Granulysin-Mediated Cytotoxicity in Colorectal Cancer Patients.

  Medicina (Kaunas), Apr 2026

• Bridging Target Recognition with Direct Molecular Counting: A DNA Framework Converter-Mediated nFCM Assay Platform for Quantifying Diverse Biochemical Analytes.

  Anal Chem, Mar 2026

• Characterization of Lymphocyte Subsets in Peripheral Blood of Patients with Colorectal Cancer.

  J Gastrointest Cancer, Feb 2026

• Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.

  Cell Oncol (Dordr), Feb 2026

• Single-cell mass cytometry reveals distinct immune signatures in colorectal cancer.

  Anal Methods, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.